ALNY
Alnylam Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$40.19B
P/E Ratio
129.82
EPS
$2.32
Beta
0.38
52W High
$495.55
52W Low
$245.96
50-Day MA
$320.98
200-Day MA
$393.04
Dividend Yield
—
Profit Margin
8.45%
Forward P/E
33.78
PEG Ratio
0.60
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $3.71B |
| Gross Profit (TTM) | $3.03B |
| EBITDA | $557.24M |
| Operating Margin | 12.00% |
| Return on Equity | 73.30% |
| Return on Assets | 6.81% |
| Revenue/Share (TTM) | $28.35 |
| Book Value | $5.96 |
| Price-to-Book | 51.08 |
| Price-to-Sales (TTM) | 10.82 |
| EV/Revenue | 10.41 |
| EV/EBITDA | 61.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 84.90% |
| Shares Outstanding | $133.43M |
| Float | $132.07M |
| % Insiders | 0.19% |
| % Institutions | 101.07% |
Historical Volatility
HV 10-Day
29.98%
HV 20-Day
36.13%
HV 30-Day
39.98%
HV 60-Day
38.03%
HV Rank
64.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($449.12 target)
6
Strong Buy14
Buy8
HoldData last updated: 4/30/2026